These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26240053)

  • 21. Nanostructured drug delivery for better management of tuberculosis.
    Kaur IP; Singh H
    J Control Release; 2014 Jun; 184():36-50. PubMed ID: 24732260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infection caused by Mycobacterium tuberculosis.
    Peloquin CA; Berning SE
    Ann Pharmacother; 1994 Jan; 28(1):72-84. PubMed ID: 8123968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.
    Xu Y; Wu J; Liao S; Sun Z
    Ann Clin Microbiol Antimicrob; 2017 Oct; 16(1):67. PubMed ID: 28974222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nano-based drug delivery optimization for tuberculosis treatment: A review.
    Dahanayake MH; Jayasundera ACA
    J Microbiol Methods; 2021 Feb; 181():106127. PubMed ID: 33359155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
    Sosnik A; Carcaboso AM; Glisoni RJ; Moretton MA; Chiappetta DA
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):547-59. PubMed ID: 19914315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanotechnology and tuberculosis: An old disease with new treatment strategies.
    Macêdo DCDS; Cavalcanti IDL; Medeiros SMFRDS; Souza JB; Lira Nogueira MCB; Cavalcanti IMF
    Tuberculosis (Edinb); 2022 Jul; 135():102208. PubMed ID: 35567896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Present status of nanoparticle research for treatment of tuberculosis.
    Shegokar R; Al Shaal L; Mitri K
    J Pharm Pharm Sci; 2011; 14(1):100-16. PubMed ID: 21501557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in Nanotechnology-Based Strategies for Bone Tuberculosis Management.
    Luo Y; Chen H; Chen H; Xiu P; Zeng J; Song Y; Li T
    Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanocarrier-based interventions for the management of MDR/XDR-TB.
    Mustafa S; Pai RS; Singh G; Kusum Devi V
    J Drug Target; 2015 May; 23(4):287-304. PubMed ID: 25766078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis.
    Rath G; Pradhan D; Ghosh G; Goyal AK
    Curr Pharm Des; 2021; 27(17):2026-2040. PubMed ID: 33634753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis--A Review.
    da Silva PB; de Freitas ES; Bernegossi J; Gonçalez ML; Sato MR; Leite CQ; Pavan FR; Chorilli M
    J Biomed Nanotechnol; 2016 Feb; 12(2):241-60. PubMed ID: 27305759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent patents and advances on anti - tuberculosis drug delivery and formulations.
    Vora C; Patadia R; Mittal K; Mashru R
    Recent Pat Drug Deliv Formul; 2013 Aug; 7(2):138-49. PubMed ID: 23244680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
    Garg T; Goyal AK; Rath G; Murthy RS
    Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current nanotechnological strategies using lipids, carbohydrates, proteins and metal conjugates-based carrier systems for diagnosis and treatment of tuberculosis - A review.
    Usharani N; Kanth SV; Saravanan N
    Int J Biol Macromol; 2023 Feb; 227():262-272. PubMed ID: 36521715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Social leverage of intellectual property: road to the development of better therapy for tuberculosis.
    Thangaraj H; Reljic R
    Recent Pat Antiinfect Drug Discov; 2009 Jun; 4(2):114-22. PubMed ID: 19519546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
    Sgaragli G; Frosini M; Saponara S; Corelli F
    Curr Med Chem; 2016; 23(21):2245-74. PubMed ID: 27142291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis drug targets.
    Zhang Y; Amzel LM
    Curr Drug Targets; 2002 Apr; 3(2):131-54. PubMed ID: 11958297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cursed duet today: Tuberculosis and HIV-coinfection.
    Tiberi S; Carvalho AC; Sulis G; Vaghela D; Rendon A; Mello FC; Rahman A; Matin N; Zumla A; Pontali E
    Presse Med; 2017 Mar; 46(2 Pt 2):e23-e39. PubMed ID: 28256380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment.
    Bartoletti M; Martelli G; Tedeschi S; Morelli M; Bertuzzo V; Tadolini M; Pianta P; Cristini F; Giannella M; Lewis RE; Pinna AD; Viale P
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28054732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.